Atea Pharmaceuticals GAAP EPS of -$0.40 misses by $0.03

2025-03-07 05:27

Atea Pharmaceuticals press release (NASDAQ:AVIR): Q4 GAAP EPS of -$0.40 misses by $0.03.
Cash, Equivalents and Marketable Securities: $454.7 million at December 31, 2024, compared to $578.1 million at December 31, 2023.
In December 2024, Atea announced that it had engaged Evercore, an independent global investment bank, to assist the Company in the exploration of strategic partnerships related to its Phase 3 program for the treatment of HCV.
Shares +0.33%.

More on Atea Pharmaceuticals